Europe is joining forces against neglected parasitic diseases - Medical News

Wednesday 5 March 2014 - 2am PSTWed 5 Mar 2014 - 2am PST

The international consortium A-PARADDISE (Anti-Parasitic Drug Discovery in Epigenetics), coordinatedjust gotten funds of €& euro; 6 million from the European Commission to perform large screening of impressive therapies against 4 overlooked leechlike diseases:, leishmaniasis, Chagas disease and. The researchers have a typical goal: to establish new drugs against the bloodsuckers that trigger these diseases. The project entails 10 European partners, 5 Brazilian partners (who operate in the area where the diseases are native to the island) and 2 Australian partners. They will all be fulfilling on 17 and 18 March at the Principle of Genetics and Molecular and Cellular The field of biology (Inserm / CNRS / College of Strasbourg Joint Research Unit), to obtain the project began.

Schistosomiasis, leishmaniasis, Chagas disease and malaria are considereded overlooked diseases due to the fact that the initiative and funds embeded establishing new therapy and control methods already not equaled with their catastrophic human effect. They affect individuals in establishing nations, basically in Africa, the Center East, South The united state and eastern Asia, in tropical and sub-tropical areas. Around one billion individuals are regularly exposed to these diseases, which trigger virtually one million fatalities each year.

Currently, there is no injection against these bloodsuckers. Additionally, the effectiveness of existing therapies is limited, eithereffects oror prospective advancement of resistance. Consequently, the A-PARADDISE consortium, which is coordinatedheaded- Director of Research at the Centre for Infection and Immunity in Lille - is concentrating on establishing new drugs against these parasitoses.

The A-PARADDISE project will use a strategy that has currently been tried and checked throughout a previous project of a comparable scale (SEtTReND), which aimed to establish drugs against schistosomiasis. The researchers checked out histone-modifying enzymes (HME), which determine the structure of the parasite's chromosomes. It was shown that some HME preventions generate cell fatality, which makes them hazardous to this parasite. This Research provided the proof of principle that HMEs act on the schistosomiasis parasite, and has actually resulted in the advancement of a bank of prospect substances which could swiftly be checked against various other human bloodsuckers.

Many thanks to the new project A-PARADDISE, researchers will manage to place the fundamental concept into technique and develop on itunique system for screening anti-parasitic drugs targeting HMEs, for integrating them into a clinical advancement program. The experimental technique consists in literally and virtually checking the effectiveness and the poisoning of the substances, in vitro and in vivo.

The ultimate goal of the A-PARADDISE project is to supply several prospect therapies against the 4 bloodsuckers and to lead the way for clinical trials in the close to future.

To ensure the success of the project, the participants were all picked for their higher degree of knowledge in their respective industries: high-throughput screening process, computer-aided screening process, the manufacturing of recombinant healthy proteins, next generation sequencing, phenotypic tests, toxicology and pharmacology.


Leave your comment